Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

Benzinga Newsdesk www.benzinga.com Positive 82.9%

Neg 0% Neu 0% Pos 82.9%

Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.